IncellDx signs liquid biopsy distribution agreement with Singapore-based Biolidics

IncellDx and Biolidics have announced that they have signed a distribution agreement for the IncellDx bioINK® PD-L1 CTC Core Kit. Biolidics will distribute the product with the Biolidics’ ClearCell® FX1 System.

The IncellDx bioINK® PD-L1 Core Kit is pre-optimized to enable highly sensitive and specific quantification of protein or mRNA expression on CTCs at a single-cell-by-cell resolution for microfluidic chips. The IncellDx proprietary fixation method minimizes clumping and aggregates of platelets and red blood cells. Further, the bioINK® preserves RNA and DNA for downstream sequencing applications following pre-identification of CTCs.

We are very excited to expand our launch of our proprietary, optimized Liquid Biopsy reagent technology contained in our bioINK® kits. This agreement covers the first of many cancer specific bioINK® kits including kits for breast cancer, lung cancer, urologic cancers, and sarcomas. In addition, we have designed the detection system for enumeration in such a way that does not eliminate the ability to perform downstream single cell sequencing for research,” added Bruce Patterson CEO of IncellDx.


Related presentations

Liked this post?

Share it on your social networks

Photonics Forums Yole CIOE 2020 1140x370